Dark

Check out our Dark Pool Levels

EVLO
EVELO BIOSCIENCES INC
stock OTC

EOD

Aug 7, 2026

0.000100USD+9900.000%(+0.000099)520

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 17, 2022

07:00AM EST Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and GlobeNewswire Inc

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Jan 4, 2022

07:00AM EST Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcoming catalysts for 2022. GlobeNewswire Inc

Dec 22, 2021

04:14PM EST Evelo Bio 8-K Shows Co. Gave Planned Updates To Study Protocol For Phase 2 Trial Of EDP1815 In Atopic Dermatitis Benzinga

Dec 14, 2021

07:26AM EST Evelo Biosciences Added To Nasdaq Biotechnology Index Benzinga

07:00AM EST Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on December 20, 2021. GlobeNewswire Inc

Nov 9, 2021

07:00AM EST Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th, 2021 at 6:20 a.m. ET (11:20 a.m. GMT). GlobeNewswire Inc

Nov 2, 2021

10:53AM EDT JMP Securities Maintains Market Outperform on Evelo Biosciences, Lowers Price Target to $41.5 Benzinga

Nov 1, 2021

08:46AM EDT Chardan Capital Upgrades Evelo Biosciences to Buy, Maintains $12 Price Target Benzinga

Oct 28, 2021

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

07:43AM EDT Evelo Biosciences Q3 EPS $(0.63) Misses $(0.54) Estimate Benzinga

07:00AM EDT Positive Phase 2 clinical data with EDP1815 in psoriasis; moving towards registration studiesDosing for Phase 2 EDP1815 Phase 2 trial in atopic dermatitis to begin during 4Q 2021Preclinical data support development of EDP1867 in neuroinflammatory diseasesManagement to host conference call at 8:30 a.m. ET GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 21, 2021

07:00AM EDT Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights. GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Benzinga

10:12AM EDT Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize PR Newswire

07:00AM EDT Data suggest SINTAX medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis Data support development of EDP1867 for the treatment of neuroinflammatory diseases GlobeNewswire Inc

Oct 4, 2021

10:55AM EDT Evelo Biosciences Sponsored Study Titled 'Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms' Posted To ClinicalTrials.Gov; Study Is Recruiting Benzinga

Sep 27, 2021

12:34PM EDT Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Mixed; US Durable Goods Orders Increase Sharply In August Benzinga

10:02AM EDT Evelo Biosciences shares were trading higher after the company announced Phase 2 clinical data with EDP1815 in Psoriasis. Benzinga

03:04AM EDT Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing SINTAX medicines, announced Monday positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. RTTNews

02:00AM EDT Clinically and statistically significant improvement in PASI-50 score achievedEDP1815 safety and tolerability data comparable to placebo in studyEDP1815 advancing towards registration studies in psoriasisManagement to host conference call at 8:00 a.m. ET GlobeNewswire Inc

Sep 20, 2021

07:01AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will host a fireside chat at the Cantor Global Healthcare Conference on Monday, September 27th, 2021 at 1:20 p.m. ET. GlobeNewswire Inc

Sep 9, 2021

07:28AM EDT Evelo Biosciences Announces Issuance of U.S. Patent for Pharmaceutical Compositions of Single Strains of Naturally Occurring Bacteria as Medicines Benzinga

07:00AM EDT Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new type of orally delivered medicines, today announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria. GlobeNewswire Inc

Sep 7, 2021

07:13AM EDT Evelo Biosciences Appoints Iain McInnes To Board Of Directors RTTNews

07:00AM EDT Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of Iain McInnes, M.B.Ch.B, Ph.D., to its Board of Directors. GlobeNewswire Inc

Aug 23, 2021

04:10PM EDT Evelo Biosciences Inc Files For Mixed Shelf Of Up To $200M Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

07:00AM EDT EDP1815 Phase 2b data in psoriasis expected in 3Q 2021Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021Strengthened leadership team with appointment of Mark Plinio as Chief Commercial OfficerMultiple clinical data readouts expected over next 6-12 monthsManagement to host conference call at 8:30 a.m. ET GlobeNewswire Inc

06:43AM EDT Evelo Biosciences Q2 EPS $(0.59) Misses $(0.54) Estimate Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 22, 2021

07:00AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights. GlobeNewswire Inc

Jul 14, 2021

04:03PM EDT Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on July 12, 2021, Ayse Kocak commenced her services as Evelos Head of International & Special Projects. GlobeNewswire Inc

Jun 23, 2021

02:00PM EDT JMP Securities Maintains Market Outperform on Evelo Biosciences, Raises Price Target to $38 Benzinga

01:24PM EDT Evelo Biosciences Shares Quiet; JP Morgan Raises Price Target From $36 To $38 Benzinga

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2021 Benzinga

07:52AM EDT Cantor Fitzgerald Initiates Coverage On Evelo Biosciences with Overweight Rating, Announces Price Target of $28 Benzinga

Jun 16, 2021

04:01PM EDT Evelo Biosciences Announces Grant of Inducement Award GlobeNewswire Inc

Jun 15, 2021

01:07PM EDT Evelo Biosciences Publishes Study Titled 'EDP1867 Phase 1a/1b Study in Healthy Participants and Participants With Moderate Atopic Dermatitis and, Optionally, Moderate Psoriasis, and/or Mild Asthma' To ClinicalTrials.Gov Site Benzinga

Jun 3, 2021

04:01PM EDT Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion of the Leadership Team, the Evelo Board of Directors has approved an inducement equity plan. GlobeNewswire Inc

Jun 1, 2021

07:00AM EDT Evelo Biosciences Announces Appointment of Mark Plinio as Chief GlobeNewswire Inc

May 26, 2021

07:00AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present at three upcoming virtual investor conferences in June: GlobeNewswire Inc

May 25, 2021

06:01AM EDT Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological PR Newswire

May 19, 2021

09:46AM EDT Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening RTTNews

09:04AM EDT Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat PR Newswire

May 13, 2021

07:00AM EDT Evelo Biosciences Presents New Preclinical Data for Extracellular GlobeNewswire Inc

May 3, 2021

08:05AM EDT Morgan Stanley Maintains Equal-Weight on Evelo Biosciences, Lowers Price Target to $13 Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

07:27AM EDT Evelo Biosciences Q1 EPS $(0.55) Misses $(0.51) Estimate Benzinga

07:00AM EDT Evelo Biosciences Reports First Quarter 2021 Financial Results and GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 22, 2021

07:00AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights. GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

04:07PM EDT Evelo Presents Full Clinical Data From Phase 1b Clinical Trial Cohort Evaluating EDP1815 RTTNews

04:07PM EDT Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis Benzinga

04:01PM EDT Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting GlobeNewswire Inc

Apr 15, 2021

07:09AM EDT Evelo Biosciences Announces Appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to the Board of Directors Benzinga

07:00AM EDT Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointments of Luca Scavo as Chief Financial Officer (CFO), effective June 1, 2021, and Julie H. McHugh to its Board of Directors, effective immediately. GlobeNewswire Inc

Apr 12, 2021

03:01PM EDT Mid-Afternoon Market Update: Dow Falls Over 100 Points; Canaan Shares Tumble After Q4 Results Benzinga

12:32PM EDT Mid-Day Market Update: Crude Oil Rises 2%; iRhythm Technologies Shares Plummet Benzinga

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2021 Benzinga

07:45AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:34AM EDT Jefferies Upgrades Evelo Biosciences to Buy, Raises Price Target to $18 Benzinga

Apr 5, 2021

07:00AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET. GlobeNewswire Inc

Mar 30, 2021

09:30AM EDT Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion PR Newswire

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

03:00AM EDT -- Collaboration expected to accelerate access to Evelos lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Healths first biotechnology licensing agreement GlobeNewswire Inc

Mar 9, 2021

09:16AM EST Evelo Biosciences Q4 EPS $(0.62) Misses $(0.53) Estimate Benzinga

07:00AM EST Evelo Biosciences Announces Fourth Quarter and Full Year 2020 GlobeNewswire Inc

04:09AM EST Earnings Scheduled For March 9, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 2, 2021

07:00AM EST Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights. GlobeNewswire Inc

Feb 16, 2021

07:00AM EST Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of John Hohneker, M.D., to its Board of Directors. GlobeNewswire Inc

Feb 6, 2021

01:27PM EST Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More Benzinga

Feb 5, 2021

06:14AM EST Evelo Biosciences 10%+ Owner Afeyan Reported Purchase of 130,000 Shares @ Avg Price of $15.00/Share in Form 4 Filing on Thursday Benzinga

Jan 29, 2021

07:45AM EST The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga

Jan 28, 2021

09:39PM EST Evelo Biosciences Prices Underwritten Public Offering Of 4.50 Mln Shares At $15.00/shr RTTNews

04:05PM EST Evelo Biosciences Announces $50M Proposed Public Offering of Common Stock Benzinga

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 21, 2021

08:05AM EST The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

07:07AM EST Evelo Biosciences Announces New Positive Confirmatory Data From Phase 1b Trial Of EDP1815 In Atopic Dermatitis RTTNews

07:00AM EST EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measuredphysician-reported outcomes GlobeNewswire Inc

Jan 19, 2021

09:20AM EST Morgan Stanley Maintains Equal-Weight on Evelo Biosciences, Raises Price Target to $14 Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

07:00AM EST -- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- GlobeNewswire Inc

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 23, 2020

01:52PM EST Evelo Biosciences shares were trading higher after JMP Securities initiated coverage on the stock with an Outperform rating and announced a price target of $27 per share. Benzinga

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 23, 2020 Benzinga

07:13AM EST JMP Securities Initiates Coverage On Evelo Biosciences with Outperform Rating, Announces Price Target of $27 Benzinga

Dec 21, 2020

07:00AM EST Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. GlobeNewswire Inc

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

10:34AM EST Shares of Evelo Biosciences, Inc. (EVLO) are rising more than 43% Monday morning, continuing the momentum from December 9, after it reported positive top line clinical data from the Phase 1b study of its drug candidate EDP1815 in mild to moderate atopic dermatitis. RTTNews

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 9, 2020

09:01AM EST Evelo Biosciences Reports New Clinical Candidate In Oncology; Presents Added Interim Data from Phase 1/2 Trial Of EDP1503 In Patients With Triple-Negative Breast Cancer Benzinga

09:00AM EST EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX product candidates to activate systemic immunity GlobeNewswire Inc

07:09AM EST Evelo Biosciences Reports Positive Topline Clinical Data In Phase 1b Trial Of EDP1815 In Atopic Dermatitis RTTNews

07:03AM EST Evelo Biosciences Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis Demonstrated Statistically And Clinically Significant Improvement Benzinga

07:00AM EST Evelo Biosciences Reports Positive Topline Clinical Data in Phase GlobeNewswire Inc

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 3, 2020

07:13AM EST Evelo Biosciences Completes Enrollment To Interim Target In Phase 2 Trial Of EDP1815 For Psoriasis RTTNews

07:00AM EST Evelo Biosciences Completes Enrollment to Interim Target in Phase GlobeNewswire Inc

Nov 11, 2020

07:59AM EST Morgan Stanley Maintains Equal-Weight on Evelo Biosciences, Lowers Price Target to $6 Benzinga

Nov 9, 2020

08:07AM EST Evelo Biosciences Presents New Preclinical Data For Anti-Tumor Effects Of Orally Delivered Microbial Extracellular Vesicles At The SITC 35th Anniversary Annual Meeting Benzinga

08:00AM EST -- EDP1908 demonstrates potent anti-tumor effects in murine models of cancer -- -- Oralextracellular vesicles have potential to be a completely novel mechanism of I/O therapy -- GlobeNewswire Inc

Oct 29, 2020

07:39AM EDT Evelo Biosciences Q3 EPS $(0.45) Beats $(0.50) Estimate Benzinga

07:38AM EDT Evelo Biosciences Announces Treated First Patients In Phase 2 Dose-ranging Trial For EDP1815 In Psoriasis Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:00AM EDT Evelo Biosciences Reports Third Quarter 2020 Financial Results and GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 22, 2020

04:01PM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and business highlights. GlobeNewswire Inc

Oct 15, 2020

07:00AM EDT Evelo Biosciences to Host Key Opinion Leader Discussion Focused on GlobeNewswire Inc

Oct 14, 2020

07:14AM EDT Evelo Completes Enrollment In Phase 1b Clinical Trial Cohort Evaluating EDP1815 In Atopic Dermatitis RTTNews

07:03AM EDT Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis Benzinga

07:00AM EDT Evelo Biosciences Completes Enrollment in Phase 1b Clinical Trial GlobeNewswire Inc

Oct 13, 2020

07:11AM EDT Evelo Biosciences Treats First Patients In Phase 2 Dose-Ranging Trial Of EDP1815 For Psoriasis RTTNews

07:06AM EDT Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis Benzinga

07:00AM EDT Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging GlobeNewswire Inc

Sep 14, 2020

07:13AM EDT Evelo Biosciences Appoints Julie Carretero As Chief People Officer RTTNews

Sep 8, 2020

07:00AM EDT Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in two upcoming virtual investor conferences in September: GlobeNewswire Inc

Jul 30, 2020

09:55AM EDT Evelo Biosciences Earlier Reported Q2 EPS $(0.63) Beats $(0.78) Estimate Benzinga

07:00AM EDT Evelo Biosciences Reports Second Quarter 2020 Financial Results GlobeNewswire Inc

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 23, 2020

07:00AM EDT Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 30, 2020 to report its second quarter 2020 financial results and discuss business highlights. GlobeNewswire Inc

Share